Ovarian Cysts Market Research Report – Global Forecast till 2023

Ovarian Cysts Market Research Report: By Type (Functional Cysts, Non-Functional Cysts) By Diagnosis (Imaging, CA-125 Blood Test, Laparoscopy) By Treatment (PCOS Drugs, Surgery) By End Users (Hospitals, Research Organization) - Global Forecast till 2023

Market Scenario:

Ovarian cysts are closed, sac-like structures filled with a liquid or semisolid substance within the ovary. Ovarian cysts are quite common in women who ovulate and the chances for the development of such cysts after menopause are less. However, the formation of ovarian cysts even after menopause is reported. This condition is marked by high risks for ovarian cancer. Most of the ovarian cysts are discovered during a routine pelvic exam. According to a study published in the Journal of Clinical Research in Paediatric Endocrinology in 2017, the frequency of ovarian cysts is about 1.8% in children aged between 5-9 years and 18.8% in those who aged between 10-18 years. Moreover, it is estimated that with the onset of adolescence and increasing age, the frequency of ovarian cysts increases and ranges between 3.8%-31.3%. Such trends in the prevalence of the ovarian cysts are one of the major drivers of the market growth. Moreover, rising healthcare expenditures and increasing awareness about woman health boost the market growth. However, lack of awareness and low per capita healthcare expenditure in the developing countries may restrain the market growth.

The global ovarian cysts market is expected to grow at an approximate CAGR of 8.2% during the forecast period.

Intended Audience

- Pharmaceutical companies
- Biotechnological institutes
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers

Figure 1:- Global ovarian cysts market share, by region
Sources: WHO, annual reports, press release, white paper, and company presentation

Segmentation

The global ovarian cysts market is segmented on the basis of type, diagnosis, treatment, and end users.

On the basis of the type, the market is segmented into functional cysts, non-functional cysts, and others. The functional cysts segment by type is sub-segmented into the follicular cyst, corpus luteum cyst, and others. The non-functional cysts segment by type is sub-segmented into dermoid cysts, cystadenomas, endometriomas, and others.

On the basis of the diagnosis, the market is segmented into imaging, CA-125 blood test, laparoscopy, and others. The imaging segment is sub-segmented into CT scan, MRI, ultrasound, and others.

On the basis of the treatment, the market is segmented into medication, polycystic ovary syndrome (PCOS) drugs, pain relievers, surgery, and others. The pain relievers are sub-segmented into acetaminophen, non-steroidal anti-inflammatory drugs, opioids, and others.

On the basis of the end users, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.

Regional Analysis

America dominates the global ovarian cysts market owing to a well-developed healthcare sector and huge patient population for ovarian cysts. Apart from this, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. In 2015, according to the Centres for Disease Control and Prevention, in the U.S. the total healthcare expenditure accounted for 17.8% of the total gross domestic product (GDP), which accounted for USD 3.2 trillion.

Europe is the second largest ovarian cysts market, which is followed by Asia Pacific. Availability of funds for research, huge patient population, increasing healthcare expenditures, well-developed healthcare sector and government support for research & development are projected to drive the market growth during the forecasted period. Regionally, Europe is divided into Western Europe and Eastern Europe. Western Europe holds the major share of the regional market, which is majorly contributed by Germany, the U.K., and France. However, Eastern Europe is the fastest growing region due to the huge opportunities in the untapped market.

Asia Pacific is the fastest growing region in the global market due to the presence of a huge patient population, continuously developing economies like India and China, and presence of huge opportunity in the market. Moreover, favorable government policies and increasing healthcare expenditures fuel the market growth within the region.

On the other hand, the Middle East & Africa holds the least share of the global ovarian cysts market due to the presence of poor economy, especially, in the African region. Majority of the market of this region is held by the Middle East due to the well-developed healthcare sector and huge healthcare
expenditure by the presence of economies like Kuwait, Saudi Arabia, Dubai, and Qatar.

Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation

Key players in global ovarian cysts market

Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (The Middle East & Africa), Quest Diagnostics Incorporated. (U.S.), Novartis AG (Europe), General Electric Company (Europe), Merck & Co., Inc. (U.S.), Boston Scientific Corporation (U.S.), and Medtronic (U.S)

Contents:

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Global Ovarian Cysts Market, by Type
6.1 Introduction
6.2 Functional Cysts
Market Estimates & Forecast, 2017 – 2023
6.2.1 Follicular cyst
6.2.2 Corpus luteum cyst
6.2.3 Others
6.3 Non-Functional Cysts
Market Estimates & Forecast, 2017 – 2023
6.3.1 Dermoid cysts
6.3.2 Cystadenomas
6.3.3 Endometriomas
6.3.4 Others
6.4 Others

Chapter 7. Global Ovarian Cysts Market, by Diagnosis
7.1 Introduction
7.2 Imaging
Market Estimates & Forecast, 2017 – 2023
7.2.1 CT scan
7.2.2 MRI
7.2.3 Ultrasound
7.2.4 Others
7.3 CA-125 Blood Test
Market Estimates & Forecast, 2017 – 2023
7.4 Laparoscopy
Chapter 8. Global Ovarian Cysts Market, by Treatment

8.1 Introduction
8.2 Medication
8.3 Polycystic Ovary Syndrome (PCOS) Drugs
8.4 Pain Relievers
8.4.1 Acetaminophen
8.4.2 Non-steroidal Anti-Inflammatory Drugs
8.4.3 Opioids
8.4.4 Others
8.5 Surgery
8.6 Others

Chapter 9. Global Ovarian Cysts Market, by End Users

9.1 Introduction
9.2 Hospitals & Clinics
9.3 Medical Institutes
9.4 Research Organization
9.5 Others

Chapter 10. Global Ovarian Cysts Market, by Region

10.1 Introduction
10.2 America
10.2.1 North America
10.2.1.1 US
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Pfizer Inc.
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.2.4 Key Developments
12.1.5 SWOT Analysis
12.2 Teva Pharmaceutical Industries Ltd.
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Quest Diagnostics Incorporated.
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Novartis AG
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis

12.5 General Electric Company
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.5.5 SWOT Analysis

12.6 Merck & Co., Inc.
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis

12.7 Boston Scientific Corporation
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis

12.8 Medtronic
12.8.1 Overview
12.8.2 Product Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis

12.9 Others

Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO's View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Ovarian Cysts Market

Chapter 14 Appendix

LIST OF TABLES
Table 1 Ovarian Cysts Industry Synopsis, 2017 – 2023
Table 42 Middle East & Africa Ovarian Cysts Market by Treatment, 2017 – 2023, (USD Million)
Table 43 Middle East & Africa Ovarian Cysts Market by End Users, 2017 – 2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Global Ovarian Cysts Market
Figure 3 Market Dynamics for Global Ovarian Cysts Market
Figure 4 Global Ovarian Cysts Market Share, by Type 2016
Figure 5 Global Ovarian Cysts Market Share, by Diagnosis 2016
Figure 6 Global Ovarian Cysts Market Share, by Treatment, 2016
Figure 7 Global Ovarian Cysts Market Share, by End Users, 2016
Figure 8 Global Ovarian Cysts Market Share, by Region, 2016
Figure 9 North America Ovarian Cysts Market Share, by Country, 2016
Figure 10 Europe Ovarian Cysts Market Share, by Country, 2016
Figure 11 Asia Pacific Ovarian Cysts Market Share, by Country, 2016
Figure 12 Middle East & Africa Ovarian Cysts Market Share, by Country, 2016
Figure 13 Global Ovarian Cysts Market: Company Share Analysis, 2016 (%)
Figure 14 Pfizer Inc.: Key Financials
Figure 15 Pfizer Inc.: Segmental Revenue
Figure 16 Pfizer Inc.: Geographical Revenue
Figure 17 Teva Pharmaceutical Industries Ltd.: Type UK Ltd: Key Financials
Figure 18 Teva Pharmaceutical Industries Ltd.: Type UK Ltd: Segmental Revenue
Figure 19 Teva Pharmaceutical Industries Ltd.: Type UK Ltd: Geographical Revenue
Figure 20 Quest Diagnostics Incorporated.: Key Financials
Figure 21 Quest Diagnostics Incorporated.: Segmental Revenue
Figure 22 Quest Diagnostics Incorporated.: Geographical Revenue
Figure 23 Novartis AG: Key Financials
Figure 24 Novartis AG: Segmental Revenue
Figure 25 Novartis AG: Geographical Revenue
Figure 26 General Electric Company: Key Financials
Figure 27 General Electric Company: Segmental Revenue
Figure 28 General Electric Company: Geographical Revenue
Figure 29 Merck & Co., Inc.: Key Financials
Figure 30 Merck & Co., Inc.: Segmental Revenue
Figure 31 Merck & Co., Inc.: Geographical Revenue
Figure 32 Boston Scientific Corporation: Key Financials
Figure 33 Boston Scientific Corporation: Segmental Revenue
Figure 34 Boston Scientific Corporation: Geographical Revenue
Figure 35 Medtronic: Key Financials
Figure 36 Medtronic: Segmental Revenue
Figure 37 Medtronic: Geographical Revenue